Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash & Equivalents (2016 - 2026)

Champions Oncology has reported Cash & Equivalents over the past 17 years, most recently at $7.1 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 121.74% year-over-year to $7.1 million; the TTM value through Jan 2026 reached $7.1 million, up 121.74%, while the annual FY2025 figure was $9.8 million, 273.76% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $7.1 million at Champions Oncology, down from $8.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $10.8 million in Q4 2022 and troughed at $2.6 million in Q2 2024.
  • A 5-year average of $6.3 million and a median of $5.5 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 50.05% in 2024 and later surged 273.76% in 2025.
  • Year by year, Cash & Equivalents stood at $10.8 million in 2022, then tumbled by 49.08% to $5.5 million in 2023, then plummeted by 50.05% to $2.8 million in 2024, then soared by 209.22% to $8.5 million in 2025, then decreased by 16.63% to $7.1 million in 2026.
  • Business Quant data shows Cash & Equivalents for CSBR at $7.1 million in Q1 2026, $8.5 million in Q4 2025, and $10.3 million in Q3 2025.